IRVING, Texas–(BUSINESS WIRE)–The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 22, 2022 a regular dividend of $0.54 per share of common stock, a 15% increase from $0.47 per share in the prior quarter. The dividend will be payable on October 3, 2022, to stockholders of record on September 1, 2022. “This dividend … [Read more…]
Tarek Hassan, MD: Past President of American Society of Retina Specialists and Retina World Congress; Clinical researcher: global randomized clinical trials (>150), peer-reviewed (230); founder 6 medical device and/or medical education companies; holder of numerous issued patents and inventions CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, Inc. a private biotechnology company located in Cambridge MA with a proprietary … [Read more…]
WASHINGTON–(BUSINESS WIRE)–Eccovia, a leading provider of cloud-based SaaS solutions for the health and human services sector, announces the release of an unprecedented data warehouse and community-analytics platform, ClientInsight. ClientInsight is hosted in Microsoft Azure and is a premier solution for data quality, performance, and actionable insights. Since the COVID-19 pandemic began, our nation’s most vulnerable … [Read more…]
Agreement will provide Lifespin with access to more than 25,000 longitudinal blood samples from approximately 4,800 oncological patients archived at Biobank Graz BOSTON–(BUSINESS WIRE)–Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has entered into a scientific collaborative agreement with Biobank Graz and the Clinical Division of Oncology of … [Read more…]
GENOA, Italy–(BUSINESS WIRE)–#autism–IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service … [Read more…]
Former Goldman Sachs Co-head of EMEA Healthcare Investment Banking, Partner and Managing Director brings extensive experience in corporate biotech and strategic finance SOMERVILLE, Mass.–(BUSINESS WIRE)–Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Jason Silvers, M.D., … [Read more…]
Castle Biosciences surpasses 100,000 orders for its flagship risk-stratification test designed to help guide risk-appropriate treatment decisions for patients diagnosed with cutaneous melanoma FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s DecisionDx®-Melanoma gene expression profile test, … [Read more…]
Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to demonstrate a survival benefit in this population Application being evaluated under FDA Real-Time Oncology Review and Project Orbis WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of ENHERTU® … [Read more…]
IRVING, Texas–(BUSINESS WIRE)–#teamvizient—Vizient, Inc., the nations’ largest member-driven health care performance improvement company, today announced a strategic partnership agreement with Mpirik, a cloud-based care pathway software company focused on cardiac care, that will enable physicians to make more informed decisions on patient care while helping to reduce undertreatment. The strategic partnership expands access to patient … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Anti-Thrombin III Testing Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering. The anti-thrombin III testing market is poised to grow by $ 161.48 mn during 2022-2026, accelerating at a CAGR of 7.73% This study identifies the presence of various blood clotting disorders as one of the prime reasons driving the anti-thrombin … [Read more…]
